Last reviewed · How we verify
Non-infectious intermediate, posterior and panuveitis
Approved treatments
- Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - CYLTEZO · BOEHRINGER INGELHEIM
- Humira · Sohag University
Clinical guidelines
- FDA label — 1L|2L
Treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-infectious intermediate, posterior and panuveitis patent landscape — cliff calendar, originator estates, attackable patents
- Non-infectious intermediate, posterior and panuveitis treatment landscape brief
- Non-infectious intermediate, posterior and panuveitis treatment updates RSS
Frequently asked questions about Non-infectious intermediate, posterior and panuveitis
What drugs treat Non-infectious intermediate, posterior and panuveitis?
Tracked treatments include Abrilada, Humira, CYLTEZO.
What is the treatment for Non-infectious intermediate, posterior and panuveitis?
Standard treatment for Non-infectious intermediate, posterior and panuveitis includes Abrilada, Humira, CYLTEZO. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Non-infectious intermediate, posterior and panuveitis?
FDA label publishes guidelines for Non-infectious intermediate, posterior and panuveitis. 1 guideline references tracked.
Related
- Treatment landscape: Non-infectious intermediate, posterior and panuveitis patent cliff · Non-infectious intermediate, posterior and panuveitis CI report
- Treatment: Abrilada · AbbVie
- Treatment: Humira · AbbVie
- Treatment: CYLTEZO · BOEHRINGER INGELHEIM
- Treatment: Humira · Sohag University
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing